SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Luigino Calzetta, Paola Rogliani, Mario Cazzola, Maria Gabriella Matera, Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond, Expert Opinion on Drug Discovery, 2014, 9, 6, 595

    CrossRef

  2. 2
    Merritt L. Fajt, Sally E. Wenzel, Biologic therapy in asthma: entering the new age of personalized medicine, Journal of Asthma, 2014, 51, 7, 669

    CrossRef

  3. 3
    Carlos E. Baena-Cagnani, R. Maximiliano Gómez, Current status of therapy with omalizumab in children, Current Opinion in Allergy and Clinical Immunology, 2014, 14, 2, 149

    CrossRef

  4. 4
    Gert-Jan Braunstahl, Janice Canvin, Guy Peachey, Chien-Wei Chen, Panayiotis Georgiou, Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting, Biologics in Therapy, 2014, 4, 1-2, 57

    CrossRef

  5. 5
    J.-P. Oster, F. Lavaud, A. Bentaleb, Y. Bloch, J.-L. Bourrain, P. Carré, G. Devouassoux, G. Newinger, M. Verdaguer, F. de Blay, Intérêt d’un traitement par omalizumab dans le cadre d’une immunothérapie spécifique. Recueil d’expérience et analyse de la littérature, Revue Française d'Allergologie, 2014, 54, 5, 347

    CrossRef

  6. 6
    Nathan Hambly, Parameswaran Nair, Monoclonal antibodies for the treatment of refractory asthma, Current Opinion in Pulmonary Medicine, 2014, 20, 1, 87

    CrossRef

  7. 7
    M. Molimard, L. Mala, I. Bourdeix, V. Le Gros, Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control, Respiratory Medicine, 2014, 108, 4, 571

    CrossRef

  8. 8
    Dilşad Mungan, Occupational Allergic Rhinitis: What Do We Know?, Current Treatment Options in Allergy, 2014,

    CrossRef

  9. 9
    Sophia Tsabouri, Xanthippi Tseretopoulou, Konstantinos Priftis, Evangelia E. Ntzani, Omalizumab for the Treatment of Inadequately Controlled Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, The Journal of Allergy and Clinical Immunology: In Practice, 2014, 2, 3, 332

    CrossRef

  10. 10
    Marc Humbert, William Busse, Nicola A. Hanania, Philip J. Lowe, Janice Canvin, Veit J. Erpenbeck, Stephen Holgate, Omalizumab in Asthma: An Update on Recent Developments, The Journal of Allergy and Clinical Immunology: In Practice, 2014, 2, 5, 525

    CrossRef

  11. 11
    Amelia Licari, Alessia Marseglia, Silvia Caimmi, Riccardo Castagnoli, Thomas Foiadelli, Salvatore Barberi, Gian Luigi Marseglia, Omalizumab in Children, Pediatric Drugs, 2014, 16, 6, 491

    CrossRef

  12. 12
    Marco Caminati, Gianenrico Senna, Fulvia Chieco Bianchi, Maria Rita Marchi, Andrea Vianello, Claudio Micheletto, Carlo Pomari, Silvia Tognella, Francesca Savoia, Valentina Mirisola, Andrea Rossi, Omalizumab management beyond clinical trials: The added value of a network model, Pulmonary Pharmacology & Therapeutics, 2014, 29, 1, 74

    CrossRef

  13. 13
    Erminia Ridolo, Marcello Montagni, Valerie Melli, Fulvio Braido, Cristoforo Incorvaia, Giorgio Walter Canonica, Pharmacotherapy of allergic rhinitis: current options and future perspectives, Expert Opinion on Pharmacotherapy, 2014, 15, 1, 73

    CrossRef

  14. 14
    Matteo Bonini, Giuseppe Di Maria, Pierluigi Paggiaro, Andrea Rossi, GianEnrico Senna, Massimo Triggiani, Giorgio Walter Canonica, Potential benefit of omalizumab in respiratory diseases, Annals of Allergy, Asthma & Immunology, 2014, 113, 5, 513

    CrossRef

  15. 15
    Laurent L. Reber, Nelly Frossard, Targeting mast cells in inflammatory diseases, Pharmacology & Therapeutics, 2014, 142, 3, 416

    CrossRef

  16. 16
    Gennaro D’Amato, Anna Stanziola, Alessandro Sanduzzi, Gennaro Liccardi, Antonello Salzillo, Carolina Vitale, Antonio Molino, Alessandro Vatrella, Maria D’Amato, Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review, Multidisciplinary Respiratory Medicine, 2014, 9, 1, 23

    CrossRef

  17. 17
    Eckard Hamelmann, Ulrich Wahn, Allergens and Allergen Immunotherapy, 2014,

    CrossRef

  18. 18
    H.G. Haggerty, K.D. Price, J.M. Shenton, Reference Module in Biomedical Sciences, 2014,

    CrossRef

  19. 19
    Garry M Walsh, An update on biologic-based therapy in asthma, Immunotherapy, 2013, 5, 11, 1255

    CrossRef

  20. 20
    K Suresh Babu, Riccardo Polosa, Jaymin B Morjaria, Anti-IgE – emerging opportunities for Omalizumab, Expert Opinion on Biological Therapy, 2013, 13, 5, 765

    CrossRef

  21. 21
    Floortje van Nooten, Sean Stern, Gert-Jan Braunstahl, Chris Thompson, Martijn Groot, Ruth E. Brown, Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands, Journal of Medical Economics, 2013, 16, 3, 342

    CrossRef

  22. 22
    Priyanka Vashisht, Thomas Casale, Omalizumab for treatment of allergic rhinitis, Expert Opinion on Biological Therapy, 2013, 13, 6, 933

    CrossRef

  23. You have free access to this content23
    G. Roberts, M. Xatzipsalti, L. M. Borrego, A. Custovic, S. Halken, P. W. Hellings, N. G. Papadopoulos, G. Rotiroti, G. Scadding, F. Timmermans, E. Valovirta, Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology, Allergy, 2013, 68, 9
  24. 24
    Matthias Volkmar Kopp, Eckard Hamelmann, Meike Bendiks, Stefan Zielen, Wolfgang Kamin, Karl-Christian Bergmann, Christian Klein, Ulrich Wahn, Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy, Pediatric Allergy and Immunology, 2013, 24, 5
  25. 25
    Roberto Walter Dal Negro, Silvia Tognella, Lorenzo Pradelli, A 36-Month Study on the Cost/Utility of Add-On Omalizumab in Persistent Difficult-to-Treat Atopic Asthma in Italy, Journal of Asthma, 2012, 49, 8, 843

    CrossRef

  26. 26
    Yukiko Iino, Mariko Hara, Masayo Hasegawa, Shingo Matsuzawa, Akihiro Shinnabe, Hiromi Kanazawa, Naohiro Yoshida, Clinical Efficacy of Anti-IgE Therapy for Eosinophilic Otitis Media, Otology & Neurotology, 2012, 33, 7, 1218

    CrossRef

  27. 27
    Makoto Hoshino, Junichi Ohtawa, Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma, Respiration, 2012, 83, 6, 520

    CrossRef

  28. 28
    Giovanni Passalacqua, Giorgio Ciprandi, Emerging drugs for perennial allergic rhinitis, Expert Opinion on Emerging Drugs, 2012, 17, 4, 543

    CrossRef

  29. 29
    Marie-Hélène Lafeuille, Jason Dean, Jie Zhang, Mei Sheng Duh, Boris Gorsh, Patrick Lefebvre, Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma, Annals of Allergy, Asthma & Immunology, 2012, 109, 1, 59

    CrossRef

  30. 30
    Eleni G. Tzortzaki, Andreas Georgiou, Dimitrios Kampas, Marinos Lemessios, Miltiadis Markatos, Tonia Adamidi, Katerina Samara, Georgia Skoula, Aggeliki Damianaki, Sophia Schiza, Nikos Tzanakis, Nikolaos M. Siafakas, Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean “real-life” experience, Pulmonary Pharmacology & Therapeutics, 2012, 25, 1, 77

    CrossRef

  31. 31
    William Busse, Roland Buhl, Carlos Fernandez Vidaurre, Martin Blogg, Jin Zhu, Mark D. Eisner, Janice Canvin, Omalizumab and the risk of malignancy: Results from a pooled analysis, Journal of Allergy and Clinical Immunology, 2012, 129, 4, 983

    CrossRef

  32. You have free access to this content32
    Christian Schumann, Cornelia Kropf, Thomas Wibmer, Stefan Rüdiger, Kathrin Magdalena Stoiber, Antje Thielen, Wolfgang Rottbauer, Claus Kroegel, Omalizumab in patients with severe asthma: the XCLUSIVE study, The Clinical Respiratory Journal, 2012, 6, 4
  33. 33
    Menachem Rottem, Omalizumab Reduces Corticosteroid Use in Patients with Severe Allergic Asthma: Real-Life Experience in Israel, Journal of Asthma, 2012, 49, 1, 78

    CrossRef

  34. 34
    Nancy M. Abdelaty, Patient characteristics that can predict response to omalizumab an (Anti-IgE Antibody) for achieving better control of asthmatic patients, Egyptian Journal of Chest Diseases and Tuberculosis, 2012, 61, 3, 15

    CrossRef

  35. 35
    Kristin Kuhl, Nicola A. Hanania, Targeting IgE in asthma, Current Opinion in Pulmonary Medicine, 2012, 18, 1, 1

    CrossRef

  36. 36
    Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli, The potential of biologics for the treatment of asthma, Nature Reviews Drug Discovery, 2012, 11, 12, 958

    CrossRef

  37. 37
    Richard B. Moss, The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis, Annals of the New York Academy of Sciences, 2012, 1272, 1
  38. 38
    Tania Mucci, Satish Govindaraj, Jody Tversky, Allergic Rhinitis, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2011, 78, 5
  39. 39
    Louis-Philippe Boulet, Marie-Ève Boulay, Asthma-related comorbidities, Expert Review of Respiratory Medicine, 2011, 5, 3, 377

    CrossRef

  40. 40
    Roberto W. Dal Negro, Massimo Guerriero, Claudio Micheletto, Silvia Tognella, Marilia Visconti, Changes in Total IgE Plasma Concentration Measured at the Third Month during Anti-IgE Treatment Predict Future Exacerbation Rates in Difficult-to-Treat Atopic Asthma: A Pilot Study, Journal of Asthma, 2011, 48, 5, 437

    CrossRef

  41. 41
    Ricardo Tan, Jonathan Corren, Omalizumab in the treatment of asthma, Expert Review of Respiratory Medicine, 2011, 5, 6, 747

    CrossRef

  42. 42
    Christoph Schäper, Sven Gläser, Stephan B. Felix, Annette Gogolka, Beate Koch, Matthias Krüll, Ralf Ewert, Oliver Noga, Omalizumab treatment and exercise capacity in severe asthmatics – Results from a pilot study, Respiratory Medicine, 2011, 105, 1, 3

    CrossRef

  43. 43
    Matthias Volkmar Kopp, Omalizumab: Anti-IgE Therapy in Allergy, Current Allergy and Asthma Reports, 2011, 11, 2, 101

    CrossRef

  44. 44
    Thuy-Anh N. Melvin, Alpen A. Patel, Pharmacotherapy for Allergic Rhinitis, Otolaryngologic Clinics of North America, 2011, 44, 3, 727

    CrossRef

  45. 45
    Henry Milgrom, Angel Fowler-Taylor, Carlos Fernandez Vidaurre, Sumedha Jayawardene, Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma, Current Medical Research and Opinion, 2011, 27, 1, 163

    CrossRef

  46. 46
    Ricardo A Tan, Jonathan Corren, Safety of omalizumab in asthma, Expert Opinion on Drug Safety, 2011, 10, 3, 463

    CrossRef

  47. 47
    Gert-Jan Braunstahl, Jo Leo, Jackie Thirlwell, Guy Peachey, Robert Maykut, Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics, Current Medical Research and Opinion, 2011, 27, 4, 761

    CrossRef

  48. 48
    Ari J Fried, Hans C Oettgen, Anti-IgE in the treatment of allergic disorders in pediatrics, Current Opinion in Pediatrics, 2010, 22, 6, 758

    CrossRef

  49. 49
    M. Massanari, S.T. Holgate, W.W. Busse, P. Jimenez, F. Kianifard, R. Zeldin, Effect of omalizumab on peripheral blood eosinophilia in allergic asthma, Respiratory Medicine, 2010, 104, 2, 188

    CrossRef

  50. 50
    Stephanie Korn, Christian Schumann, Cornelia Kropf, Kathrin Stoiber, Antje Thielen, Christian Taube, Roland Buhl, Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma, Annals of Allergy, Asthma & Immunology, 2010, 105, 4, 313

    CrossRef

  51. 51
    H.L. Grossman, Amory Schlender, Peter Alperin, Elizabeth L. Stanley, Jie Zhang, Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma, Current Medical Research and Opinion, 2010, 26, 12, 2779

    CrossRef

  52. 52
    M. Kulus, J. Hébert, E. Garcia, A. Fowler Taylor, C. Fernandez Vidaurre, M. Blogg, Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma, Current Medical Research and Opinion, 2010, 26, 6, 1285

    CrossRef

  53. 53
    Ken Ohta, Manabu Yamamoto, Norio Sato, Kimitoshi Ikeda, Terumasa Miyamoto, One Year Treatment with Omalizumab Is Effective and Well Tolerated in Japanese Patients with Moderate-to-Severe Persistent Asthma, Allergology International, 2010, 59, 2, 167

    CrossRef

  54. 54
    Wolfgang Kamin, Matthias Volkmar Kopp, Frank Erdnuess, Uwe Schauer, Stefan Zielen, Ulrich Wahn, Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously, Pediatric Allergy and Immunology, 2010, 21, 1-Part-II
  55. 55
    Thomas B. Casale, Jeffrey Stokes, Anti-IgE therapy: Clinical utility beyond asthma, Journal of Allergy and Clinical Immunology, 2009, 123, 4, 770

    CrossRef

  56. 56
    Paula J Busse, Kiran Kilaru, Complexities of Diagnosis and Treatment of Allergic Respiratory Disease in the Elderly, Drugs & Aging, 2009, 26, 1, 1

    CrossRef

  57. 57
    Robert A. Nathan, Management of Patients with Allergic Rhinitis and Asthma: Literature Review, Southern Medical Journal, 2009, 102, 9, 935

    CrossRef

  58. 58
    Jaymin B Morjaria, Riccardo Polosa, Off-label use of omalizumab in non-asthma conditions: new opportunities, Expert Review of Respiratory Medicine, 2009, 3, 3, 299

    CrossRef

  59. 59
    Leandro Fritscher, Kenneth R Chapman, Omalizumab for asthma: pharmacology and clinical profile, Expert Review of Respiratory Medicine, 2009, 3, 2, 119

    CrossRef

  60. 60
    S. Korn, A. Thielen, S. Seyfried, C. Taube, O. Kornmann, R. Buhl, Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany, Respiratory Medicine, 2009, 103, 11, 1725

    CrossRef

  61. 61
    M. Humbert, L. P. Boulet, R. M. Niven, Z. Panahloo, M Blogg, G. Ayre, Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis, Allergy, 2009, 64, 1
  62. 62
    Elizabeth J. Mahoney, Ralph Metson, Palliative Care for the Patient with Refractory Chronic Rhinosinusitis, Otolaryngologic Clinics of North America, 2009, 42, 1, 39

    CrossRef

  63. 63
    Glenis Scadding, Pediatric allergy medications: review of currently available formulations, Current Medical Research and Opinion, 2009, 25, 8, 2069

    CrossRef

  64. 64
    Cidália Rodrigues, Michele de Santis, Ana Maria Arrobas, Jorge Pires, Rinite alérgica e doenças associadas, Revista Portuguesa de Pneumologia (English Edition), 2009, 15, 5, 891

    CrossRef

  65. 65
    Stephen Holgate, Roland Buhl, Jean Bousquet, Nicola Smith, Zoya Panahloo, Pablo Jimenez, The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update, Respiratory Medicine, 2009, 103, 8, 1098

    CrossRef

  66. 66
    Jeffrey R. Stokes, Thomas B. Casale, Middleton's Allergy: Principles and Practice, 2009,

    CrossRef

  67. 67
    M. Humbert, W. Berger, G. Rapatz, F. Turk, Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma, Allergy, 2008, 63, 5
  68. 68
    Richard W. Weber, Allergic Rhinitis, Primary Care: Clinics in Office Practice, 2008, 35, 1, 1

    CrossRef

  69. 69
    J. Bousquet, N. Khaltaev, A. A. Cruz, J. Denburg, W. J. Fokkens, A. Togias, T. Zuberbier, C. E. Baena-Cagnani, G. W. Canonica, C. Van Weel, I. Agache, N. Aït-Khaled, C. Bachert, M. S. Blaiss, S. Bonini, L.-P. Boulet, P.-J. Bousquet, P. Camargos, K.-H. Carlsen, Y. Chen, A. Custovic, R. Dahl, P. Demoly, H. Douagui, S. R. Durham, R. Gerth Van Wijk, O. Kalayci, M. A. Kaliner, Y.-Y. Kim, M. L. Kowalski, P. Kuna, L. T. T. Le, C. Lemiere, J. Li, R. F. Lockey, S. Mavale-Manuel, E. O. Meltzer, Y. Mohammad, J. Mullol, R. Naclerio, R. E. O’Hehir, K. Ohta, S. Ouedraogo, S. Palkonen, N. Papadopoulos, G. Passalacqua, R. Pawankar, T. A. Popov, K. F. Rabe, J. Rosado-Pinto, G. K. Scadding, F. E. R. Simons, E. Toskala, E. Valovirta, P. Van Cauwenberge, D.-Y. Wang, M. Wickman, B. P. Yawn, A. Yorgancioglu, O. M. Yusuf, H. Zar, I. Annesi-Maesano, E. D. Bateman, A. Ben Kheder, D. A. Boakye, J. Bouchard, P. Burney, W. W. Busse, M. Chan-Yeung, N. H. Chavannes, A. Chuchalin, W. K. Dolen, R. Emuzyte, L. Grouse, M. Humbert, C. Jackson, S. L. Johnston, P. K. Keith, J. P. Kemp, J.-M. Klossek, D. Larenas-Linnemann, B. Lipworth, J.-L. Malo, G. D. Marshall, C. Naspitz, K. Nekam, B. Niggemann, E. Nizankowska-Mogilnicka, Y. Okamoto, M. P. Orru, P. Potter, D. Price, S. W. Stoloff, O. Vandenplas, G. Viegi, D. Williams, Allergic Rhinitis and its Impact on Asthma (ARIA) 2008, Allergy, 2008, 63,
  70. 70
    S. D. Sullivan, F. Turk, An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma, Allergy, 2008, 63, 6
  71. 71
    Sonja A. Grundmann, Pia B. Hemfort, Thomas A. Luger, Randolf Brehler, Anti-IgE (omalizumab): A new therapeutic approach for chronic rhinosinusitis, Journal of Allergy and Clinical Immunology, 2008, 121, 1, 257

    CrossRef

  72. 72
    Manav Segal, Jeffrey R. Stokes, Thomas B. Casale, Anti-Immunoglobulin E Therapy, World Allergy Organization Journal, 2008, 1, 10, 174

    CrossRef

  73. 73
    I. Baiardini, F. Braido, F. Tarantini, A. Porcu, S. Bonini, P.-J. Bousquet, T. Zuberbier, P. Demoly, G. W. Canonica, ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN Review, Allergy, 2008, 63, 6
  74. 74
    J.A. Castillo Laita, J. De Benito Fernández, A. Escribano Montaner, M. Fernández Benítez, S. García de la Rubia, J. Garde Garde, L. García-Marcos, C. González Díaz, M. Ibero Iborra, M. Navarro Merino, C. Pardos Martínez, J. Pellegrini Belinchon, J. Sánchez Jiménez, J. Sanz Ortega, J.R. Villa Asensi, Consensus Statement on the Management of Paediatric Asthma. Update 2007, Allergologia et Immunopathologia, 2008, 36, 1, 31

    CrossRef

  75. 75
    Mathieu Molimard, Frédéric de Blay, Alain Didier, Vincent Le Gros, Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in France, Respiratory Medicine, 2008, 102, 1, 71

    CrossRef

  76. 76
    R. Niven, K.F. Chung, Z. Panahloo, M. Blogg, G. Ayre, Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study, Respiratory Medicine, 2008, 102, 10, 1371

    CrossRef

  77. 77
    Rosita Saraceno, Sergio Chimenti, How to manage infections in the era of biologics?, Dermatologic Therapy, 2008, 21, 3
  78. 78
    Thomas B. Casale, Jeffrey R. Stokes, Immunomodulators for allergic respiratory disorders, Journal of Allergy and Clinical Immunology, 2008, 121, 2, 288

    CrossRef

  79. 79
    Jenny M. Campbell, Jonathan D. Wofford, Alan P. Knutsen, Omalizumab Treatment in Children 6 to 18 Years Old with Severe Asthma at a Children’s Medical Center, Pediatric Asthma, Allergy & Immunology, 2008, 21, 3, 129

    CrossRef

  80. 80
    I. Baiardini, F. Braido, S. Brandi, F. Tarantini, S. Bonini, P. J. Bousquet, T. Zuberbier, P. Demoly, G. W. Canonica, The impact of GINA suggested drugs for the treatment of asthma on Health-Related Quality of Life: a GA2LEN review, Allergy, 2008, 63, 8
  81. 81
    Marc Humbert, Gilles Garcia, Pascal Chanez, Thérapeutiques immunologiques ciblées dans l’asthme sévère, La Presse Médicale, 2008, 37, 1, 173

    CrossRef

  82. 82
    E Haydn Walters, Julia AE Walters, Richard Wood-Baker, Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma, Expert Opinion on Pharmacotherapy, 2007, 8, 5, 585

    CrossRef

  83. 83
    Jaymin B Morjaria, Gnanasekaran Gnanakumaran, Kesavan Suresh Babu, Anti-IgE in allergic asthma and rhinitis: an update, Expert Opinion on Biological Therapy, 2007, 7, 11, 1739

    CrossRef

  84. 84
    Howard FOX, Anti-IgE in severe persistent allergic asthma, Respirology, 2007, 12,
  85. 85
    F. Tarantini, I. Baiardini, G. Passalacqua, F. Braido, G. W. Canonica, Asthma treatment: ‘magic bullets which seek their own targets’, Allergy, 2007, 62, 6
  86. 86
    A. Nopp, S. G. O. Johansson, J. Ankerst, M. Palmqvist, H. Öman, CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment, Allergy, 2007, 62, 10
  87. 87
    A. A. Cruz, T. Popov, R. Pawankar, I. Annesi-Maesano, W. Fokkens, J. Kemp, K. Ohta, D. Price, J. Bousquet, Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA2LEN, Allergy, 2007, 62,
  88. 88
    J.A. Castillo Laita, J. De Benito Fernández, A. Escribano Montaner, M. Fernández Benítez, S. García de la Rubia, J. Garde Garde, L. García-Marcos, C. González Díaz, M. Ibero Iborra, M. Navarro Merino, C. Pardos Martínez, J. Pellegrini Belinchon, J. Sánchez Jiménez, J. Sanz Ortega, J.R. Villa Asensi, Consenso sobre tratamiento del asma en pediatría, Anales de Pediatría, 2007, 67, 3, 253

    CrossRef

  89. 89
    O. Pfaar, L. Klimek, Die Anwendung von humanisierten Anti-Immunoglobulin-E-Antikörpern, HNO, 2007, 55, 12, 981

    CrossRef

  90. 90
    Pedro C. Avila, Does Anti-IgE Therapy Help in Asthma? Efficacy and Controversies, Annual Review of Medicine, 2007, 58, 1, 185

    CrossRef

  91. 91
    William W. Busse, Marc Massanari, Farid Kianifard, Gregory P. Geba, Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis, Current Medical Research and Opinion, 2007, 23, 10, 2379

    CrossRef

  92. 92
    M.A. Martin-Mateos, Monoclonal antibodies in Pediatrics: use in prevention and treatment, Allergologia et Immunopathologia, 2007, 35, 4, 145

    CrossRef

  93. 93
    Carlos E Baena-Cagnani, Giovanni Passalacqua, Maximiliano Gómez, Mario E Zernotti, G Walter Canonica, New perspectives in the treatment of allergic rhinitis and asthma in children, Current Opinion in Allergy and Clinical Immunology, 2007, 7, 2, 201

    CrossRef

  94. 94
    Julia E. Graves, Kara Nunley, Michael P. Heffernan, Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2), Journal of the American Academy of Dermatology, 2007, 56, 1, e55

    CrossRef

  95. 95
    J. Bousquet, K. Rabe, M. Humbert, K.F. Chung, W. Berger, H. Fox, G. Ayre, H. Chen, K. Thomas, M. Blogg, S. Holgate, Predicting and evaluating response to omalizumab in patients with severe allergic asthma, Respiratory Medicine, 2007, 101, 7, 1483

    CrossRef

  96. 96
    H. William Kelly, Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines, Journal of Allergy and Clinical Immunology, 2007, 120, 5, 989

    CrossRef

  97. 97
    A. A. Cruz, F. Lima, E. Sarinho, G. Ayre, C. Martin, H. Fox, P. J. Cooper, Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection, Clinical & Experimental Allergy, 2007, 37, 2
  98. 98
    Zuzana Diamant, J. Diderik Boot, J. Christian Virchow, Summing up 100 years of asthma, Respiratory Medicine, 2007, 101, 3, 378

    CrossRef

  99. 99
    Paul P Belliveau, Monina R Lahoz, Treating Allergic Asthma with Omalizumab, Disease Management & Health Outcomes, 2007, 15, 3, 165

    CrossRef

  100. 100
    Tse Wen Chang, Pheidias C. Wu, C. Long Hsu, Alfur F. Hung, 2007,

    CrossRef

  101. 101
    P. W. Hellings, W. J. Fokkens, Allergic rhinitis and its impact on otorhinolaryngology, Allergy, 2006, 61, 6
  102. 102
    Alexander N. Greiner, Allergic Rhinitis: Impact of the Disease and Considerations for Management, Medical Clinics of North America, 2006, 90, 1, 17

    CrossRef

  103. 103
    G. Passalacqua, Allergic rhinitis: the nose and beyond, Allergy, 2006, 61, 11
  104. 104
    P. Cabrera-Navarro, Anti-Immunoglobulin E, a Monoclonal Antibody to Treat Respiratory Disorders, Archivos de Bronconeumología ((English Edition)), 2006, 42, 5, 241

    CrossRef

  105. 105
    Pedro Cabrera Navarro, Anticuerpos monoclonales en la terapéutica neumológica, Archivos de Bronconeumología, 2006, 42, 2

    CrossRef

  106. 106
    P. Cabrera-Navarro, Antiinmunoglobulina E, un anticuerpo monoclonal, en el tratamiento de las enfermedades respiratorias, Archivos de Bronconeumología, 2006, 42, 5, 241

    CrossRef

  107. 107
    M. Humbert, Asthma, a priority for the allergist, Allergy, 2006, 61, 5
  108. 108
    L. Prieto, V. Gutiérrez, C. Colás, A. Tabar, C. Pérez-Francés, L. Bruno, S. Uixera, Effect of Omalizumab on Adenosine 5′-Monophosphate Responsiveness in Subjects with Allergic Asthma, International Archives of Allergy and Immunology, 2006, 139, 2, 122

    CrossRef

  109. 109
    Graeme P Currie, Effects of asthma treatment: the present and future, Expert Review of Clinical Immunology, 2006, 2, 4, 547

    CrossRef

  110. 110
    Kimberly Niebauer, Sarah Dewilde, Julia Fox-Rushby, Dennis A. Revicki, Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma, Annals of Allergy, Asthma & Immunology, 2006, 96, 2, 316

    CrossRef

  111. 111
    Bradley Chipps, Roland Buhl, Kai-Michael Beeh, Howard Fox, Karen Thomas, Colin Reisner, Improvement in quality of life with omalizumab in patients with severe allergic asthma, Current Medical Research and Opinion, 2006, 22, 11, 2201

    CrossRef

  112. 112
    Dennis Nowak, Management of asthma with anti-immunoglobulin E: A review of clinical trials of omalizumab, Respiratory Medicine, 2006, 100, 11, 1907

    CrossRef

  113. 113
    Giovanni Passalacqua, Giorgio Ciprandi, Novel therapeutic interventions for allergic rhinitis, Expert Opinion on Investigational Drugs, 2006, 15, 12, 1615

    CrossRef

  114. 114
    Justin Clark, Dean Chiang, Thomas B. Casale, Omalizumab in the Treatment of Allergic Respiratory Disease, Journal of Asthma, 2006, 43, 2, 87

    CrossRef

  115. 115
    Pedro Cabrera Navarro, José Carlos Rodríguez Gallego, Perfil farmacológico del omalizumab, Archivos de Bronconeumología, 2006, 42, 26

    CrossRef

  116. 116
    J. Bousquet, P. Van Cauwenberge, N. Aït Khaled, C. Bachert, C. E. Baena-Cagnani, J. Bouchard, C. Bunnag, G. W. Canonica, K.-H. Carlsen, Y.-Z. Chen, A. A. Cruz, A. Custovic, P. Demoly, R. Dubakiene, S. Durham, W. Fokkens, P. Howarth, J. Kemp, M. L. Kowalski, V. Kvedariene, B. Lipworth, R. Lockey, V. Lund, S. Mavale-Manuel, E. O. Meltzer, J. Mullol, R. Naclerio, K. Nekam, K. Ohta, N. Papadopoulos, G. Passalacqua, R. Pawankar, T. Popov, P. Potter, D. Price, G. Scadding, F. E. R. Simons, V. Spicak, E. Valovirta, D.-Y. Wang, B. Yawn, O. Yusuf, Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN), Allergy, 2006, 61, 9
  117. 117
    S. Dewilde, F. Turk, M. Tambour, T. Sandström, The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients:adaptation of INNOVATE to Sweden, Current Medical Research and Opinion, 2006, 22, 9, 1765

    CrossRef

  118. 118
    Pascal Demoly, Jean Bousquet, The relation between asthma and allergic rhinitis, The Lancet, 2006, 368, 9537, 711

    CrossRef

  119. 119
    Gennaro D??Amato, Enrica Bucchioni, Virginio Oldani, Walter Canonica, Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab), Treatments in Respiratory Medicine, 2006, 5, 6, 393

    CrossRef

  120. 120
    Stephen P. Peters, Gary Ferguson, Yamo Deniz, Colin Reisner, Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment, Respiratory Medicine, 2006, 100, 7, 1139

    CrossRef

  121. 121
    Carlos Villasante Fernández-Montes, Utilidad clínica del omalizumab, Archivos de Bronconeumología, 2006, 42, 32

    CrossRef

  122. 122
    Roland Buhl, Anti-IgE antibodies for the treatment of asthma, Current Opinion in Internal Medicine, 2005, 4, 2, 184

    CrossRef

  123. 123
    S. T. Holgate, R. Djukanović, T. Casale, J. Bousquet, Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy, Clinical & Experimental Allergy, 2005, 35, 4
  124. 124
    F.-X. Blanc, Asthme sévère, IgE et anti-IgE : de l’attente sceptique à l’apprentissage par les faits, Revue des Maladies Respiratoires, 2005, 22, 6, 925

    CrossRef

  125. 125
    M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hébert, J. Bousquet, K.-M. Beeh, S. Ramos, G. W. Canonica, S. Hedgecock, H. Fox, M. Blogg, K. Surrey, Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE, Allergy, 2005, 60, 3
  126. 126
    Giorgio Ciprandi, Giovanni Passalacqua, Emerging anti-inflammatory agents for allergic rhinitis, Expert Opinion on Emerging Drugs, 2005, 10, 4, 689

    CrossRef

  127. 127
    Richard A. Krathen, Sylvia Hsu, Failure of omalizumab for treatment of severe adult atopic dermatitis, Journal of the American Academy of Dermatology, 2005, 53, 2, 338

    CrossRef

  128. 128
    D. Inführ, R. Crameri, R. Lamers, G. Achatz, Molecular and cellular targets of anti-IgE antibodies, Allergy, 2005, 60, 8
  129. 129
    Thomas M. Leath, Manav Singla, Stephen P. Peters, Novel and emerging therapies for asthma, Drug Discovery Today, 2005, 10, 23-24, 1647

    CrossRef

  130. 130
    R. Aboutaam, P. Scheinmann, J. de Blic, Perspectives pédiatriques des anti-IgE, Revue Française d'Allergologie et d'Immunologie Clinique, 2005, 45, 7, 550

    CrossRef

  131. 131
    C. Serrano, A. Valero, C. Picado, Rhitinis and Asthma: One Airway, One Disease, Archivos de Bronconeumología ((English Edition)), 2005, 41, 10, 569

    CrossRef

  132. 132
    C. Serrano, A. Valero, C. Picado, Rinitis y asma: una vía respiratoria, una enfermedad, Archivos de Bronconeumología, 2005, 41, 10, 569

    CrossRef

  133. 133
    Liam G Heaney, Douglas S Robinson, Severe asthma treatment: need for characterising patients, The Lancet, 2005, 365, 9463, 974

    CrossRef

  134. 134
    Thomas Sandström, Targeting immunoglobulin E as a novel treatment for asthma, Current Allergy and Asthma Reports, 2005, 5, 2, 109

    CrossRef

  135. 135
    J. Bousquet, P. Cabrera, N. Berkman, R. Buhl, S. Holgate, S. Wenzel, H. Fox, S. Hedgecock, M. Blogg, G. Della Cioppa, The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma, Allergy, 2005, 60, 3
  136. 136
    M. Humbert, A.-B. Tonnel, Traitement par anticorps anti-IgE de l’asthme allergique difficile à contrôler, Revue des Maladies Respiratoires, 2005, 22, 6, 983

    CrossRef

  137. 137
    S Johansson, Roland Buhl, Pharmacotherapy of Asthma, 2005,

    CrossRef

  138. 138
    Guy Brusselle, Romain Pauwels, Pharmacotherapy of Asthma, 2005,

    CrossRef

  139. 139
    Jaine Brownell, Thomas B. Casale, Anti-IgE therapy, Immunology and Allergy Clinics of North America, 2004, 24, 4, 551

    CrossRef

  140. 140
    R. Louis, Anti-IgE: a significant breakthrough in the treatment of airway allergic diseases, Allergy, 2004, 59, 7
  141. 141
    Samantha Walker, Michele Monteil, Kieran Phelan, Toby J Lasserson, E. Haydn Walters, Anti-IgE for chronic asthma in adults and children, The Cochrane Library,
  142. 142
    Sharmilee M. Nyenhuis, William W. Busse, Novel Biologicals Alone and in Combination in Asthma and Allergy,
  143. 143
    Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters, Parameswaran Nair, Omalizumab for asthma in adults and children, The Cochrane Library,
  144. 144
    Kornkiat Snidvongs, Larry Kalish, Raymond Sacks, Jonathan C Craig, Richard J Harvey, Topical steroid for chronic rhinosinusitis without polyps, The Cochrane Library,